SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and extreme volatility after Novo Nordisk filed a patent infringement lawsuit over its compounded semaglutide products, which Hims has since ceased, with the community sharply divided between concerns over legal and regulatory risks and the belief that the stock is oversold with short-squeeze potential.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as community excitement builds over impending EU approval for its Anktiva therapy and Saudi Arabia's expanding commitment to "all cancers" with IBRX, with many anticipating a significant short squeeze. Investors see the company as deeply undervalued, driven by its innovative immunotherapy's potential for widespread adoption in immune restoration and cancer treatment.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending after a sharp stock drop driven by a deteriorated financial outlook, unexpected leadership changes, a delayed filing, and an SEC probe into its accounting practices, leading to a community split between those seeing an oversold buying opportunity and others fearing significant financial irregularities.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

monday.com is experiencing a sharp decline after issuing weaker-than-expected guidance and withdrawing long-term targets, intensifying market fears that AI could disrupt its traditional software business model. The community is sharply divided, with some viewing the brutal sell-off as an overreaction given the company's strong cash position and enterprise growth, while others believe AI tools pose a significant threat to the SaaS sector.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following an 'Overweight' initiation and bullish price target from Morgan Stanley, amplifying the narrative around its strategic pivot to AI and high-performance computing data centers. The community is actively discussing the company's strong power infrastructure and key partnerships, like Google, positioning it favorably amidst booming demand for computing capacity, despite some noting its historical correlation with Bitcoin prices.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean ($RIG) is trending as the community reacts to its recent all-stock acquisition of Valaris ($VAL) for $5.8 billion, a deal many see as creating a premier offshore drilling leader poised to capitalize on an emerging multi-year upcycle, though some investors are debating the implications of the merger for share dilution and the combined company's future.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending amid a significant stock plunge despite a reported earnings beat and new share buyback, fueled by concerns over Meta's Instagram developing a rival app. The community is sharply divided, with many blaming CEO Evan Spiegel's leadership while others see an extreme oversold opportunity given its user growth and AR smartglasses ambitions.

Valaris Ltd. engages in the provision of offshore contract drilling services to the international oil and gas industry. It operates through the following segments: Floaters, Jackups, ARO, and Other. The Floaters segment includes drillships and semisubmersible rigs. The Other segment is involved in management services on rigs owned by third-parties and the activities associated with arrangements with ARO under the bareboat charter arrangements. The company was founded in 1975 and is headquartered in Hamilton, Bermuda.

Valaris Ltd

Valaris is trending following the announcement of its all-stock acquisition by Transocean for approximately $5.8 billion, leading to significant community discussion around the deal's implications for shareholders and warrants. This M&A activity coincides with Valaris securing substantial new drilling contracts and ongoing conversations about a strengthening offshore energy sector.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending amidst divided community sentiment surrounding its recent or anticipated earnings, as investors debate whether growth in AI data center and silicon carbide can outweigh ongoing automotive sector weakness and margin pressures. The company's partnership with NVIDIA and a large share repurchase program are key discussion points fueling both bullish and bearish perspectives.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is gaining significant attention for its central role in advanced semiconductor packaging, which is vital for the booming AI sector and enhanced by strategic collaborations with industry leaders like Apple, Nvidia, and TSMC. The community views the company as a key beneficiary of the U.S. manufacturing reshoring trend, anticipating substantial long-term growth as it expands its domestic capabilities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?

NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.

Viking Therapeutics (NASDAQ:VKTX) Shares Pass Below Fifty Day Moving Average - Should You Sell?

Viking Therapeutics (NASDAQ:VKTX) Stock Price Passes Below Fifty Day Moving Average - Should You Sell...

<ul class="summary-bullets"><li>For the quarter ended December, Viking is expected to report a loss per share of $0.91, compared to the loss of $0.32 reported in the corresponding quarter of 2024,&nbsp;</li><li>The subcutaneous formulation of Viking Therapeutics' lead candidate VK2735 is currently in late-stage trials for obesity.</li><li>Viking CEO Brian Lian said at a conference in January that the strategic interest in weight-loss drug deals is broader than it appears.</li></ul><p><br>Shares of Viking Therapeutics (VKTX) fell 2% on Tuesday amid rising retail chatter as the company gears up to report its fourth-quarter (Q4) results.</p><p>According to Stocktwits data, message volume around VKTX stock more than tripled over the past 24 hours as of Tuesday morning.</p><p>Retail sentiment around VKTX stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.</p><h2 class="st-heading-2">What’s Retail Thinking?</h2><p>A Stocktwits user termed recent stock price action as “terrible” but noted possibilities of acquisition for the company.</p><p><stembedurl>https://www.stocktwits.com/SPG565/message/643844828</stembedurl></p><p>Another voiced hope for the company’s upcoming obesity drug taking a huge chunk off the business of bigshots Novo Nordisk and Eli Lilly and Company.</p><p><stembedurl>https://www.stocktwits.com/TrustButVerifi/message/643841493</stembedurl></p><h2 class="st-heading-2">Earnings Estimates</h2><p>Viking, a clinical-stage biotech company with no marketed products, is expected to report its Q4 2025 earnings as early as Wednesday.</p><p>For the quarter ended December, the company is expected to report a loss per share of $0.91, compared to the loss of $0.32 reported in the corresponding quarter of 2024, according to data from Fiscal AI. &nbsp;</p><h2 class="st-heading-2">Viking’s Pipeline</h2><p>The subcutaneous formulation of Viking Therapeutics' lead candidate VK2735 is currently in late-stage trials for obesity. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.</p><p>The company is also studying a tablet formulation of the drug.</p><h2 class="st-heading-2">Hopes For A Deal</h2><p>Viking CEO Brian Lian said at a conference in January that the strategic interest in weight-loss drug deals is broader than it appears.</p><p>"I think the interest is probably broader than is visible. I think that there are more parties sort of circling around the space and very intrigued," Lian said while adding that he thinks there is a "fair amount of interest” across the industry.</p><p>Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.</p><p>“...having a larger party involved would be, you know, very helpful in driving the program through commercialization,” he said. “That said, I don't think it's mandatory. I think it's probably a preference, but it's not mandatory. We're prepared to go alone, but we're also prepared to engage with anybody who's interested.”</p><p><a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has dropped 7% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-continues-to-rejig-lineup-in-run-up-to-vehicle-autonomy/cZb0GTWR4mS">Tesla Continues To Rejig Lineup In Run Up To Vehicle Autonomy</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report

According to Stocktwits data, message volume around VKTX stock more than tripled over the past 24 hours as of Tuesday morning. 

Equity

AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC

AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline.

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $29.06, signifying a -3.9% move from its prior day's close.

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

NVO faces slowing Wegovy and Ozempic sales momentum, pricing pressures and fierce competition ahead of Q4 earnings.

Viking Therapeutics to Report Q4 Earnings: Here's What to Know

VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.

Roche Reports Upbeat Efficacy Data From Phase II Obesity Study

RHHBY reports encouraging phase II data as CT-388 delivers strong, sustained weight loss and metabolic benefits in adults with obesity or overweight.

Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?

NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results?

Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.90	--	--	N/A
Q3 '25	-$0.70	-$0.81	-15.17%	MISSED
Q2 '25	-$0.45	-$0.58	-29.90%	MISSED
Q1 '25	-$0.33	-$0.41	-25.00%	MISSED
Q4 '24	-$0.27	-$0.32	-17.65%	MISSED

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest VKTX News

VKTXViking Therapeutics Inc